Lumibird Medical is proud to announce that it has received marketing approval in China for its Vitra 2 photocoagulation laser from the Chinese Health Authority (NMPA).
This significant product in the Lumibird Medical group’s range of lasers for the treatment of retinal pathologies (AMD, diabetic retinopathy) reinforces Lumibird’s position on the Chinese market with the support of its distribution partner, Gaush.
This registration, which comes after a long period of examination, will have an impact on sales of Vitra 2 in China as of the second quarter. It paves the way for further market approvals in China for key products in the range. For the year 2023, the launch of the Vitra 2 alone should enable us to increase our sales by 25%, compared to a revenue 8 million in China in 2022.
After a contracted period since 2021 on the Chinese market (Covid effect, administrative delays…), Lumibird Medical intends to continue the implementation of sales of its products with hospitals in China with growth prospects on all its ranges.
For more information about Vitra 2, visit our website for healthcare professionnals: